These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 35309935)

  • 1. The Pan-Cancer Crosstalk Between the
    Xie R; Yuan M; Jiang Y
    Front Cell Dev Biol; 2022; 10():790947. PubMed ID: 35309935
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy.
    Liang Z; Wang X; Dong K; Li X; Qin C; Zhou H
    Biomed Res Int; 2021; 2021():5575704. PubMed ID: 33977106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinoma.
    Huang S; Dong C; Zhang J; Fu S; Lv Y; Wu J
    Front Mol Biosci; 2022; 9():943384. PubMed ID: 36052169
    [No Abstract]   [Full Text] [Related]  

  • 4. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EFNA3 Is a Prognostic Biomarker Correlated With Immune Cell Infiltration and Immune Checkpoints in Gastric Cancer.
    Zheng P; Liu X; Li H; Gao L; Yu Y; Wang N; Chen H
    Front Genet; 2021; 12():796592. PubMed ID: 35126464
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer.
    Jiao Z; Feng X; Cui Y; Wang L; Gan J; Zhao Y; Meng Q
    BMC Cancer; 2022 Aug; 22(1):871. PubMed ID: 35945523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
    Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
    Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Expression of RTN1 in Lung Adenocarcinoma and 
Its Effect on Immune Microenvironment].
    Zhu S; Zu L; Xu S
    Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Xiao Y; Zhang H; Du G; Meng X; Wu T; Zhou Q; Wang Y; Tan B
    Technol Cancer Res Treat; 2020; 19():1533033820970684. PubMed ID: 33176601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
    Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
    Front Immunol; 2019; 10():6. PubMed ID: 30761122
    [No Abstract]   [Full Text] [Related]  

  • 14. CDK1 Acts as a Prognostic Biomarker Associated with Immune Infiltration in Pan-Cancer, Especially in Gastrointestinal Tumors.
    Shen J; Gong X; Tan S; Zhang Y; Xia R; Xu S; Wang S; Zhou H; Jiang Y; Zhao T; Zhang Y; Tang H; Wang C
    Curr Med Chem; 2024 Jun; ():. PubMed ID: 38952160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CALD1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers.
    Liu Y; Xie S; Zhu K; Guan X; Guo L; Lu R
    Heliyon; 2021 Jun; 7(6):e07257. PubMed ID: 34189308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of ferroptosis-related subtypes, characteristics of TME infiltration and development of prognostic models in gastric cancer.
    Tang X; Yu Y; Liu N; Su Y; Zhang K; Zhai Z; Chen C; Sun W; Chen D; Ling R
    Int Immunopharmacol; 2024 Mar; 130():111610. PubMed ID: 38402832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMA1 is potent prognostic marker and associates with immune infiltration in gastric cancer.
    Shi S; Ye S; Mao J; Ru Y; Lu Y; Wu X; Xu M; Zhu T; Wang Y; Chen Y; Tang X; Xi Y
    Autoimmunity; 2020 Jun; 53(4):210-217. PubMed ID: 32129682
    [No Abstract]   [Full Text] [Related]  

  • 18.
    Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
    Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
    [No Abstract]   [Full Text] [Related]  

  • 19. Mapk14 is a Prognostic Biomarker and Correlates with the Clinicopathological Features and Immune Infiltration of Colorectal Cancer.
    Wang D; Peng L; Hua L; Li J; Liu Y; Zhou Y
    Front Cell Dev Biol; 2022; 10():817800. PubMed ID: 35141222
    [No Abstract]   [Full Text] [Related]  

  • 20. EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma.
    Deng M; Tong R; Zhang Z; Wang T; Liang C; Zhou X; Hou G
    Cancer Cell Int; 2021 Oct; 21(1):535. PubMed ID: 34645436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.